Clients in the media Clients IN the MEDIA

Ensuring your story is visible.
Fierce-Pharma

Chiasma posts data on benefits of oral acromegaly drug over long-acting injectable rivals

Chiasma has released phase 3 data supporting its belief that acromegaly patients will prefer to take its oral formulation over existing long-acting injectables.

Here’s what makes 4 promising COVID-19 vaccines unique — and potentially useful

How it works: The San Francisco–based company engineered a common cold virus called an adenovirus to carry instructions for making two coronavirus proteins into human cells.  There, the proteins can be made to prime the immune system to later fend off the coronavirus.

GEN

Anima Biotech Heads for the Light with Up-to-$2.4B Takeda Partnership

Anima specializes in treating targets long viewed as “undruggable” by targeting cellular mechanisms that regulate mRNA translation of proteins with specific biological roles in coordinating and regulating translation of individual mRNAs and pathways . . .

Protein misfolding specialist Gain nets $40m from IPO

Gain Therapeutics has priced its initial public offering, raising more than $40 million for its computational drug discovery platform and pipeline of drugs for diseases associated with protein misfolding. 

Led by ex-Springworks exec, Pyxis forges deal to gain access to Pfizer’s ADCs, platform tech

Pyxis CEO Lara Sullivan has struck a deal with her former employer, Pfizer, that adds two preclinical therapies to the biotech’s pipeline as well as a license to the pharma’s ADC platform. 

Takeda spreads it bets in Huntington’s

The Japanese company put down another marker in the disease today by teaming up with the private Israeli company Anima Biotech, in a transaction worth $120m up front.

biospace

Immune Regulation’s Rebrand Reflects ‘Revolutionary’ Approach to Autoimmune Diseases

New Orleans-based Revolo Biotherapeutics, formerly known as Immune Regulation, rebranded to reflect its revolutionary scientific approach to dramatically alter the autoimmune and allergic disease treatment landscape.

biospace

Anima Biotech and Takeda Enter Collab to Target mRNA Translation with Small Molecules

Anima Biotech’s strategic collaboration with Takeda Pharmaceutical, just announced today, uses its novel platform for discovery of mRNA translation modulators to discover and develop a new class of therapies for neurological diseases.